GDHEC CO.,LTD(600673) 智通财经网·2025-03-31 01:16Core Insights - Dongyangguang Changjiang Pharmaceutical's "inclusion in Stock Connect" is a pivotal topic for 2024, with significant interest from northbound capital since its inclusion last September [1][2] - The company has seen a substantial increase in northbound capital investment, with holdings rising from 11.99% to 25.57% since its inclusion [1] Financial Performance - In 2024, the company reported revenue of 3.724 billion RMB, with a gross profit of 2.794 billion RMB and a net profit attributable to shareholders of 483 million RMB [3] - Research and development (R&D) expenditure reached 493 million RMB, marking a year-on-year increase of 156.62% [3] Product Development - The company's insulin product line generated 137 million RMB in revenue, a significant increase of 101.14% year-on-year, with five insulin products approved for market [4] - The innovative drug HEC88473, a dual agonist for GLP-1/FGF21, has a licensing agreement worth 938 million USD, highlighting the company's strong position in the market [5][7] Market Trends - The global market for GLP-1 drugs is projected to reach 90 billion USD by 2030, indicating a robust growth opportunity for the company [5] - The company’s first innovative drug, Emetine Phosphate Capsules, achieved revenue of 89.49 million RMB, reflecting a 120.06% increase year-on-year [6] Innovation and AI Integration - The company is leveraging AI in drug development, with a focus on enhancing innovation capabilities through advanced AI-driven models [9][10] - A partnership with Huawei Cloud aims to optimize drug molecular properties and streamline the drug discovery process, significantly improving efficiency [11] Strategic Positioning - The company is transitioning towards a growth model centered on innovative drugs and AI healthcare, moving away from traditional pharmaceutical development [12] - Continuous investment from northbound capital indicates a growing recognition of the company's value in the current market environment [12]